Evidence map›Paper›PMID 33228759›Full record

ArticleBMC research notes2020

The miRNA 196a2 rs11614913 variant has prognostic impact on Turkish patients with multiple myeloma.

Melya Pelin Kirik, Mustafa Pehlivan, Ayse Feyda Nursal, Yasemin Oyaci, Sacide Pehlivan, Istemi Serin

Abstract read
In one paragraph

Article in BMC research notes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Effect ofTechnology in cancer research & treatment
    Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Melya Pelin KirikDepartment of Hematology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
Mustafa PehlivanDepartment of Hematology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
Ayse Feyda NursalDepartment of Medical Genetics, Faculty of Medicine, Hitit University, Corum, Turkey.
Yasemin OyaciDepartment of Medical Biology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Sacide PehlivanDepartment of Medical Biology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Istemi SerinDepartment of Hematology, Istanbul Training and Research Hospital, University of Health Sciences, Org.Nafiz GURMAN CAD. 34098, Istanbul, Turkey. serinistemi@hotmail.com.ORCID http://orcid.org/0000-0003-1855-774X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMultiple myeloma (MM) arises from malignant plasma cells as a single clone in the bone marrow. Accumulating evidences have reported that there is an association between miR-196a2 (rs11614913) variant and various cancers while there were unverified and inconsistent results in MM. The goal of this study is to investigate the impact of the miR-196a2 variant on clinical findings and susceptibility in MM. Two hundred MM patients (156 patients under transplantation of autologous stem cell) and 200 healthy controls included in this study.

resultsThe statistical analysis showed no significant relationship for allele and frequencies of miR-196a2 genotype between patients and controls (p > 0.05). Log-rank test showed that gender has highly significant impact on both OS and PFS (p = 0.027, p = 0.045). In the univariate analysis, TT genotype (p = 0.022), and CT/TT (p = 0.008) had better OS. In the multivariate analysis, CC/CT-TT were associated with positively OS (p = 0.041). Currently, the most valuable prognostic markers in MM that has clinical implication are genetic abnormalities. It can be concluded from the results that miR-1962a variant is effective in prognosis of the MM. It is believed that these findings will help us understand the molecular basis of disease.

Indexed as

Case-Control StudiesGenetic Predisposition to DiseaseGenotypeHumansMicroRNAsMultiple MyelomaPolymorphism, Single NucleotidePrognosisMicroRNAsMIRN196 microRNA, humanAutologous stem cell transplantationmiR-196a2Multiple myelomaPrognosis

Identifiers

PMID33228759
PMCPMC7682760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.